Today: 29 April 2026
Browse Category

NYSE:HIMS 5 December 2025 - 23 April 2026

Hims Adds Lilly’s Zepbound and Foundayo as GLP-1 Price Fight Moves Online

Hims Adds Lilly’s Zepbound and Foundayo as GLP-1 Price Fight Moves Online

Hims & Hers Health said Thursday its providers can now send prescriptions for Eli Lilly’s Zepbound and Foundayo to LillyDirect, expanding branded obesity drug options on its platform. The move follows a similar deal with Novo Nordisk in March. Hims listed Foundayo from $149 a month and Zepbound from $299. The company previously stopped advertising compounded GLP-1s amid tighter U.S. regulations.
23 April 2026
···
Hims & Hers Health Stock Jumps as FDA Reconsiders Peptide Restrictions

Hims & Hers Health Stock Jumps as FDA Reconsiders Peptide Restrictions

Hims & Hers Health shares rose to $26.65 Thursday after the FDA said it would reconsider restrictions on several peptides, removing 12 from a high-risk list and scheduling a July review of seven more. The move follows Hims’ March decision to stop advertising compounded GLP-1 drugs and expand branded offerings through Novo Nordisk. The company acquired a California peptide facility last year to bolster supply.
16 April 2026
···
Hims & Hers Stock Surges as FDA Reopens Peptide Rules, Shifting Focus Beyond GLP-1 Drama

Hims & Hers Stock Surges as FDA Reopens Peptide Rules, Shifting Focus Beyond GLP-1 Drama

Hims & Hers Health shares rose 14% to $24.29 after the FDA said it will review restrictions on several peptides, including BPC-157 and TB-500. The agency set a July advisory meeting and will remove some peptides from its safety-risk list within a week. Hims, which acquired a California peptide facility last year, reported $2.35 billion in 2025 revenue and 2.511 million subscribers.
15 April 2026
··
Hims & Hers Health stock price steadies after wild Novo week as focus shifts to margins

Hims & Hers Health stock price steadies after wild Novo week as focus shifts to margins

Hims & Hers Health shares traded near $23.82 Friday after a volatile week sparked by its new obesity-drug deal with Novo Nordisk. Under the agreement, Hims will sell FDA-approved Wegovy and Ozempic at Novo’s prices and stop advertising compounded GLP-1 drugs. Analysts warn the shift to branded drugs could hurt margins, with Hims needing far more subscriptions to offset lost profits. The FDA and Eli Lilly have stepped up scrutiny of compounded weight-loss drugs.
13 March 2026
·
Hims & Hers stock price slides again as Novo Nordisk lawsuit tightens the screws on Wegovy copies

Hims & Hers stock price slides again as Novo Nordisk lawsuit tightens the screws on Wegovy copies

Hims & Hers Health shares fell 5.6% to $18.25 Tuesday after Novo Nordisk filed a U.S. patent lawsuit seeking to block sales of compounded versions of its Wegovy weight-loss drug. The FDA has said semaglutide is no longer in shortage, tightening rules on compounding. Hims pulled its $49 compounded semaglutide pill days after launch. Investors await Hims’ earnings on Feb. 23.
10 February 2026
···
Hims & Hers stock sinks after $49 Wegovy copycat U-turn and Novo Nordisk lawsuit

Hims & Hers stock sinks after $49 Wegovy copycat U-turn and Novo Nordisk lawsuit

Hims & Hers Health shares plunged 16% in after-hours trading Monday after the company pulled its $49 compounded semaglutide pill amid a patent lawsuit from Novo Nordisk. The stock touched $16.44 before recovering some losses. Novo seeks a court order to stop sales of unapproved compounded drugs. Leerink Partners cut its price target on Hims, citing uncertainty over future sales of compounded semaglutide.
10 February 2026
···
Dow futures steady as Wall Street braces for delayed jobs report and CPI after tech jitters

Dow futures steady as Wall Street braces for delayed jobs report and CPI after tech jitters

Dow futures rose 46 points premarket Monday while S&P 500 and Nasdaq 100 futures slipped. Kroger jumped 6% after a report naming Greg Foran as incoming CEO. Hims & Hers fell after pulling its $49 weight-loss pill following regulatory pressure. Traders awaited delayed January payrolls data and Friday’s CPI report.
9 February 2026
········
Eli Lilly stock: what to watch Monday after FDA pressure forces Hims to pull a weight-loss pill

Eli Lilly stock: what to watch Monday after FDA pressure forces Hims to pull a weight-loss pill

Eli Lilly shares rose 3.7% to $1,058.18 Friday after Hims & Hers said it would halt sales of a compounded weight-loss pill following an FDA warning. U.S. regulators said they will crack down on mass-marketed, non-approved GLP-1 drugs. The FDA threatened legal action against violators and referred Hims to the Justice Department. Investors are watching for enforcement impact on obesity-drug pricing.
8 February 2026
···
Novo Nordisk stock: Class B shares face Monday test after FDA squeeze forces Hims to pull $49 Wegovy copycat

Novo Nordisk stock: Class B shares face Monday test after FDA squeeze forces Hims to pull $49 Wegovy copycat

Novo Nordisk Class B shares closed up 5.3% at 295.50 Danish crowns in Copenhagen after Hims & Hers said it would stop offering a compounded pill version of Wegovy following U.S. regulatory warnings. The move came after Novo called the Hims product “illegal mass compounding” and threatened legal action. Shares had fallen nearly 8% Thursday after Hims launched the pill. Trading resumes Monday.
7 February 2026
··
Eli Lilly stock pops as FDA targets cheap weight-loss copycats — what to know before Monday

Eli Lilly stock pops as FDA targets cheap weight-loss copycats — what to know before Monday

Eli Lilly shares rose 3.7% to $1,058.18 Friday after the FDA said it would act against telehealth firm Hims & Hers for marketing a $49 compounded weight-loss pill. The move followed a sharp selloff Thursday when Hims announced plans to sell a version of Novo Nordisk’s Wegovy. Investors remain uncertain how aggressively regulators will police copycat drugs and pricing in the obesity drug market.
7 February 2026
····
Hims & Hers (HIMS) stock slips again as $49 Wegovy copy draws FDA heat and Novo legal threat

Hims & Hers (HIMS) stock slips again as $49 Wegovy copy draws FDA heat and Novo legal threat

Hims & Hers Health shares fell 2.6% to $22.88 Friday after launching a $49 compounded version of Novo Nordisk’s Wegovy weight-loss pill. Novo called the move “illegal mass compounding” and threatened legal action, while the FDA warned it would act against unapproved copycat drugs. Hims said its pill uses “liposomal technology” to aid absorption but gave no details. Nearly a third of Hims shares are out on loan for short bets.
6 February 2026
·
Eli Lilly stock rebounds after FDA flags copycat weight-loss drugs; what’s next for LLY

Eli Lilly stock rebounds after FDA flags copycat weight-loss drugs; what’s next for LLY

Eli Lilly shares rose 3% Friday after the FDA chief warned of a crackdown on non-approved copycat weight-loss drugs. The rebound followed an 8% drop Thursday, triggered by news of a $49 compounded rival to Novo Nordisk’s Wegovy. Investors are watching Lilly’s 2026 outlook and the FDA’s April decision on its oral obesity drug. Fourth-quarter revenue jumped 43% to $19.3 billion, led by strong sales of Mounjaro and Zepbound.
6 February 2026
····
Hims & Hers stock dips in premarket as GLP-1 drug pricing pressure stays in focus

Hims & Hers stock dips in premarket as GLP-1 drug pricing pressure stays in focus

Hims & Hers Health shares fell 0.5% to $32.87 in premarket trading Wednesday after closing down 3.1% the previous session. The move follows price cuts by Novo Nordisk and Eli Lilly on obesity drugs in China, raising questions about future margins and demand for GLP-1 therapies. Hims recently launched its weight-loss membership in the UK, offering access to Wegovy and Mounjaro.
31 December 2025
····
Hims Stock (HIMS) Outlook for 2026: Latest News, Canada Expansion, Buyback and Price Targets as of December 6, 2025

Hims Stock (HIMS) Outlook for 2026: Latest News, Canada Expansion, Buyback and Price Targets as of December 6, 2025

Hims & Hers Health (NYSE: HIMS) closed at about $39–39.3 per share on December 5, 2025, with a market cap near $9 billion. The company authorized a new $250 million share buyback after completing its previous $100 million program. Hims reported nearly 50% year-over-year revenue growth and remains profitable. Shares have swung between $24 and $73 over the past year.
6 December 2025
·
Hims & Hers Health (HIMS) Stock Today: Canada Expansion, Labs, GLP‑1 Growth and Fresh “Strong Buy” Call – Price, News & Forecast as of December 5, 2025

Hims & Hers Health (HIMS) Stock Today: Canada Expansion, Labs, GLP‑1 Growth and Fresh “Strong Buy” Call – Price, News & Forecast as of December 5, 2025

Hims & Hers Health shares closed at $40.02 on December 4, up nearly 8%, following a Q3 revenue jump of 49% to $599 million and guidance for Q4 revenue of $605–625 million. The company announced a $250 million buyback, two acquisitions, and a new chief policy officer. Shares remain well below the 52-week high of $72.98, with short interest elevated and volatility high.
5 December 2025
··
1 2

Stock Market Today

  • Blockworks aims to be the Morningstar of crypto with new fundraising and acquisitions
    April 29, 2026, 10:14 AM EDT. Blockworks, a crypto startup, plans to dominate as a data provider for cryptocurrency and tokenized assets. The company secured a Series A round extension led by ParaFi Capital and Reciprocal Ventures, valuing it at $192 million, and intends to acquire rivals to expand its platform. Co-founder Jason Yanowitz highlighted a trust gap in crypto, with insufficient institutional-grade data and research compared to traditional finance tools like Morningstar and Moody's. Blockworks' annual recurring revenue surged over 500% last year, fueled partly by its Digital Assets Summit. The firm wants to unify fragmented crypto data services, improving trader access to reliable information and potentially accelerating digital asset adoption.

Latest article

Lemonade Stock Jumps as Q1 Revenue Surge Sharpens Its 2026 Profit Test

Lemonade Stock Jumps as Q1 Revenue Surge Sharpens Its 2026 Profit Test

29 April 2026
Lemonade Inc reported first-quarter revenue of $258 million, up 71% from a year earlier, and narrowed its net loss to $35.8 million, or 47 cents a share. Shares rose 5.6% in premarket trading after results beat estimates. In-force premium climbed 32% to $1.33 billion, with customers up 23% to 3.14 million. The company raised its 2026 outlook and now expects full-year revenue of up to $1.203 billion.
Biogen Cuts 2026 Profit Forecast After Q1 Beat as Leqembi Sales Surge

Biogen Cuts 2026 Profit Forecast After Q1 Beat as Leqembi Sales Surge

29 April 2026
Biogen lowered its 2026 adjusted earnings forecast to $14.25–$15.25 per share, citing research and development charges from recent acquisitions. First-quarter revenue rose 2% to $2.48 billion, with adjusted earnings of $3.57 per share, beating analyst estimates. Leqembi sales climbed 74% to $168 million globally.
Visa Stock Jumps as Earnings Beat and $20 Billion Buyback Ease Spending Fears

Visa Stock Jumps as Earnings Beat and $20 Billion Buyback Ease Spending Fears

29 April 2026
Visa shares jumped 5% premarket Wednesday after the company beat quarterly profit estimates, raised its full-year outlook, and announced a $20 billion buyback. Adjusted net income rose to $6.3 billion, or $3.31 a share, topping forecasts. Payments volume climbed 9%, cross-border volume 12%. Visa cited resilient consumer spending but flagged Middle East tensions as a risk to travel flows.
Go toTop